Giraffe Bio's engineered molecules tackle the coming copper crunch
A biotech startup is using custom-designed compounds to help mines extract significantly more copper from existing operations, addressing a looming supply gap that could reach 25% by 2040.
Copper demand is set to outpace supply as artificial intelligence infrastructure and global electrification drive consumption upward. Projections suggest a 25% shortfall between available copper and what the world needs by 2040.
Mining companies traditionally respond to supply pressures by developing new mines, a strategy hampered by substantial costs and uncertain outcomes. Only 0.3% of prospective mining operations ultimately become productive.
Several startups have begun exploring biotechnology solutions to increase copper yields from existing operations. Companies like Endolith, Ceibo, and Transition Metal Solutions are leveraging microorganisms and microbial enhancement techniques, primarily targeting heap leaching processes where biological activity helps separate minerals from surrounding material.
Giraffe Bio has chosen a different path. The company manufactures mineral-specific chemical compounds designed to boost copper recovery by as much as 5% from existing mining operations. According to Alejandro Buffo Sempé, the company's co-founder and CEO, "is really very material" in mining contexts, where most operators consider gains of 1% to 2% successful.
The startup's competitive advantage stems from its ability to engineer compounds tailored to the particular mineral composition of individual mining sites. Rather than introducing live microorganisms directly into mining environments, Giraffe Bio cultivates engineered microbes within bioreactors to generate these specialized molecules, which are then incorporated into a mine's existing operational workflow.
Buffo Sempé explained the rationale: "We can leverage all of the biological machinery without having to deal with keeping alive a microbe, which is very complicated in [mining] environments."
Giraffe Bio has secured $6.4 million in seed funding led by Orion Industrial Ventures. BHP Ventures, Twynam, Air Capital, and Baruch Future Ventures also participated in the round, according to exclusive information obtained by TechCrunch.
The company's compounds function within the flotation process, a standard mining technique where chemicals cause certain minerals to either float or sink in water, enabling operators to separate desirable materials. Giraffe Bio's molecules bind selectively to copper, maximizing recovery rates. The startup is also developing depressor compounds that bind to unwanted materials like arsenic, causing them to sink and leaving more valuable products at the surface.
While Giraffe Bio is launching with copper, the platform can be adapted for other minerals. "The beauty of this is that we can target copper or we can target gold or silver," Buffo Sempé said.
Beyond production gains, Giraffe Bio's approach offers environmental benefits. The company's biomolecules can replace conventional flotation chemicals that carry significant environmental risks. "Instead of pouring chemicals that are usually very harmful for the environment and so forth, we're replacing the function that they are providing to the flotation process with a biomolecule," Buffo Sempé said. "We're minimizing the friction towards maximizing the output."